ANDA 215637, held by Accord Healthcare. Metoprolol Succinate.
As of Nov 21, 2026, ANDA 215637 (Metoprolol Succinate), held by Accord Healthcare, was first approved by FDA on Oct 18, 2022, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2022 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Metoprolol SuccinateEQ 50MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Metoprolol SuccinateEQ 100MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Metoprolol SuccinateEQ 200MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Jan 24, 2025 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Oct 18, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters